Antibody to the central region of human T-lymphotropic virus type 1 gp46 is associated with the progression of adult T-cell leukemia

Cancer Science

Volumn 98, Issue 2, 2007, Pages 240-245

  Sagara, Yasuko ^a   Inoue, Yukiko ^a   Ohshima, Koichi ^b   Kojima, Eijiro ^a   Utsunomiya, Atae ^c   Tsujimura, Mitsushi ^a   Shiraki, Hiroshi ^a   Kashiwagi, Seizaburo ^a  

^a Japanese Red Cross Kyushu Block Blood Center   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLING; SEQUENCE ANALYSIS; SEROCONVERSION; T CELL LEUKEMIA; TREATMENT RESPONSE; VIRUS CARRIER; VIRUS INFECTION;

ANTIBODIES, VIRAL; DISEASE PROGRESSION; EPITOPES; GENE PRODUCTS, ENV; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; PREVALENCE; RECURRENCE; RETROVIRIDAE PROTEINS, ONCOGENIC; TREATMENT OUTCOME;

EID: 33845668286     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00370.x     Document Type: Article

References (36)

1. Hinuma Y, Nagata K, Hanaoka M et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-80.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-19.
3. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79: 428-37.
4. Okamura J, Utsunomiya A, Tanosaki R et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105: 4143-5.
5. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients. Vox Sang 1984; 46: 245-53.
6. Sagara Y, Inoue Y, Shiraki H, Jinno A, Hoshino H, Maeda Y. Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins using synthetic peptides. J Virol 1996; 70: 1564-9.
7. Sagara Y, Ishida C, Inoue Y, Shiraki H, Maeda Y. 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J Virol 1998; 72: 535-41.
8. Sagara Y, Shiraki H. How does lipid in plasma membrane participate in viral infection? In: Mohan RM, ed. Research Advances in Virology, Vol. 2. India: Global Research Network, 2002; 69-81.
9. Blot V, Delamarre L, Perugi F et al. Human Dlg protein binds to the envelope glycoproteins of human T-cell leukemia virus type 1 and regulates envelope mediated cell-cell fusion in T lymphocytes. J Cell Sci 2004; 117: 3983-93.
10. Pinon JD, Klasse PJ, Jassal SR et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003; 77: 9922-30.
11. + T cells. J Virol 2005; 79: 12692-702.
12. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003; 115: 449-59.
13. Washitani Y, Kuroda N, Shiraki H et al. Linear antigenic regions of the structural proteins of human T-cell lymphotropic virus type 1 detected by enzyme-linked immunosorbent assays using synthetic peptides as antigens. J Clin Microbiol 1992; 30: 287-90.
14. Sagara Y, Inoue Y, Tsujimura M, Kojima E, Shiraki H, Kashiwagi S. Novel biomarker of HTLV-1-associated disease: Specific appearance of antibody recognizing the receptor-binding site on HTLV-1 envelope protein. Cancer Sci 2004; 95: 835-9.
15. Tobinai K, Shimoyama M, Minato K et al. Japan Clinical Oncology Group (JCOG) trial of second-generation 'LSG4 protocol' in aggressive lymphoma including ATL: Prognostic factors and a predictive model. Proc Am Soc Clin Oncol 1994; 13: 378.
16. Utsunomiya A, Miyazaki Y, Takatsuki Y et al. Improved outcome of adult T-cell leukemia/lymphoma by allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 15-20.
17. Watanabe M, Ohsugi T, Shoda M et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells: DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106: 2462-71.
18. Yamada Y, Tomonaga M, Fukuda H. et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clin Oncol Group Study 9303. Br J Haematol 2001; 113: 375-82.
19. Arisawa K, Katamine S, Kamihira S et al. A nested case-control study of risk factors for adult T-cell leukemia/lymphoma among human T-cell lymphotropic virus type-I carriers in Japan. Cancer Causes Control 2002; 13: 657-63.
20. Araki K, Harada K, Nakamoto K, Shiroma M, Miyakuni T. Clinical significance of soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol 2000; 119: 259-63.
21. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003; 22: 5131-40.
22. Yasunaga J, Matsuoka M. Leukemogenesis of adult T-cell leukemia. Int J Hematol 2003; 78: 312-20.
23. Wong-Staal F, Gallo RC. Human T-lymphotropic retroviruses. Nature 1985; 317: 395-403.
24. Kondo T, Kono H, Miyamoto N et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989; 43: 1061-4.
25. Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology 2005; 2: 16-18.
26. Hisada M, Okayama A, Spiegelman D, Mueller NE, Stuver SO. Sex-specific mortality from adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Int J Cancer 2001; 91: 497-9.
27. Hisada M, Okayama A, Shoiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998; 92: 3557-61.
28. Etoh K, Yamaguchi K, Tokudome S et al. Rapid quantification of HTLV-1 provirus load: Detection of monoclonal proliferation of HTLV-1-infected cells among blood donors. Int J Cancer 1999; 81: 859-64.
29. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: Pathways to cancer and neurodegeneration. Virology 2003; 308: 1-12.
30. Kannagi M, Ohashi T, Harashima N, Hanabuchi S, Hasegawa A. Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends Microbiol 2004; 12: 346-52.
31. Okayama A, Stuver S, Matsuoka M et al. Role of HTLV-I proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 2004; 110: 621-5.
32. Yashiki S, Fujiyoshi T, Arima N et al. HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA B*4801 alleles predispose to adult T cell leukemia: The limited recognition of HTLV type 1 Tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 Tax CD8+ cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 2001; 17: 1047-61.
33. Kawano F, Tsubada H, Yamaguchi K et al. Unusual clinical courses of adult T-cell leukemia in siblings. Cancer 1984; 54: 131-4.
34. Miyamoto Y, Yamaguchi K, Nishimura H et al. Familial adult T-cell leukemia. Cancer 1985; 55: 181-5.
35. Yamaguchi K, Yul LS, Shimizu T et al. Concurrence of lymphoma type adult T-cell leukemia in three sisters. Cancer 1985; 56: 1688-90.
36. Inoue Y, Kuroda N, Shiraki H, Sato H, Maeda Y. Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I. Int J Cancer 1992; 52: 877-80.